Resveratrol: A multifunctional cytoprotective molecule

Current Pharmaceutical Biotechnology

Volumn 11, Issue 8, 2010, Pages 810-818

  Juhasz, Bela ^a   Varga, Balazs ^a   Gesztelyi, Rudolf ^a   Kemeny Beke, Adam ^b   Zsuga, Judit ^c   Tosaki, Arpad ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Resveratrol

Indexed keywords

ALCOHOL; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTECTIVE AGENT; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; RESVERATROL; VASCULOTROPIN; ANTILIPEMIC AGENT; PLANT MEDICINAL PRODUCT; STILBENE DERIVATIVE;

ALCOHOL CONSUMPTION; ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CELL PROTECTION; DISEASE ASSOCIATION; ENZYME INHIBITION; HEART INFARCTION PREVENTION; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; ISCHEMIA; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RED WINE; REPERFUSION INJURY; REVIEW; UPREGULATION; WESTERN BLOTTING; CELL DEATH; CHEMISTRY; DRUG EFFECT; HUMAN; OXIDATIVE STRESS; PHYSIOLOGY; PHYTOTHERAPY;

ANIMALIA;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL DEATH; CYTOPROTECTION; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT PREPARATIONS; REPERFUSION INJURY; STILBENES;

EID: 79954627959     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110793262079     Document Type: Review

References (106)

1. Orallo, F. Comparative studies of the antioxidant effects of cis-and trans-resveratrol. Curr. Med. Chem., 2006, 13(1), 87-98.
2. Rupprich, N.; Hildebrand, H.; Kindl, H. Substrate specificity in vivo and in vitro in the formation of stilbenes. Biosynthesis of rhaponticin. Arch. Biochem. Biophys., 1980, 200(1), 72-78.
3. Aggarwal, B. B.; Bhardwaj, A.; Aggarwal, R. S.; Seeram, N. P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004, 24(5A), 2783-2840.
4. Schubert, R.; Fischer, R.; Hain, R.; Schreier, P. H.; Bahnweg, G.; Ernst, D.; Sandermann, H. Jr., An ozone-responsive region of the grapevine resveratrol synthase promoter differs from the basal pathogen-responsive sequence. Plant Mol. Biol., 1997, 34(3), 417-426.
5. Celotti, E.; Ferrarini, R.; Zironi, R.; Conte, L. S. Resveratrol content of some wines obtained from dried Valpolicella grapes: Recioto and Amarone. J. Chromatogr., 1996, 730(1-2), 47-52.
6. Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W.; Fong, H. H.; Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G.; Moon, R. C.; Pezzuto, J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275(5297), 218-220.
7. Langcake, P.; Pryce, R. J. A new class of phytoalexins from grapevines. Experientia, 1977, 33(2), 151-152.
8. Schoeppner, A.; Kindl, H. Stilbene synthase (pinosylvine synthase) and its induction by ultraviolet light. FEBS Lett., 1979, 108(2), 349-352.
9. Hain, R.; Bieseler, B.; Kindl, H.; Schroder, G.; Stocker, R. Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol. Biol., 1990, 15(2), 325-335.
10. Kopp, P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur. J. Endocrinol., 1998, 138(6), 619-620.
11. Stervbo, U.; Vang, O.; Bonnesen, C. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem., 2007, 101(2), 449-457.
12. Poulain, M.; Pes, G. M.; Grasland, C.; Carru, C.; Ferrucci, L.; Baggio, G.; Franceschi, C.; Deiana, L. Identification of a geographic area characterized by extreme longevity in the Sardinia island: the AKEA study. Exp. Gerontol., 2004, 39(9), 1423-1429.
13. Murakami, A.; Ishida, H.; Kobo, K.; Furukawa, I.; Ikeda, Y.; Yonaha, M.; Aniya, Y.; Ohigashi, H. Suppressive effects of Okinawan food items on free radical generation from stimulated leukocytes and identification of some active constituents: implications for the prevention of inflammation-associated carcinogenesis. Asian Pac. J. Cancer Prev., 2005, 6(4), 437-448.
14. Renaud, S.; de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet, 1992, 339(8808), 1523-1526.
15. Das, D. K.; Sato, M.; Ray, P. S.; Maulik, G.; Engelman, R. M.; Bertelli, A. A.; Bertelli, A. Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp. Clin. Res., 1999, 25(2-3), 115-120.
16. Sun, A. Y.; Simonyi, A.; Sun, G. Y. The "French Paradox" and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med., 2002, 32(4), 314-318.
17. Pearl, R. Alcohol and longevity. Mol. Gen. Genet., 1926, 49(1), 338-339.
18. Gronbaek, M.; Becker, U.; Johansen, D.; Gottschau, A.; Schnohr, P.; Hein, H. O.; Jensen, G.; Sorensen, T. I. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann. Intern. Med., 2000, 133(6), 411-419.
19. Li, J. M.; Mukamal, K. J. An update on alcohol and atherosclerosis. Curr. Opin. Lipidol., 2004, 15(6), 673-680.
20. Guiraud, A.; de Lorgeril, M.; Boucher, F.; Berthonneche, C.; Rakotovao, A.; de Leiris, J. Cardioprotective effect of chronic low dose ethanol drinking: insights into the concept of ethanol preconditioning. J. Mol. Cell Cardiol., 2004, 36(4), 561-566.
21. Pedersen, A.; Johansen, C.; Gronbaek, M. Relations between amount and type of alcohol and colon and rectal cancer in a Danish population based cohort study. Gut, 2003, 52(6), 861-867.
22. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.; Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.; de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444(7117), 337-342.
23. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5(6), 493-506.
24. Das, D. K.; Maulik, N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., 2006, 6(1), 36-47.
25. Murry, C. E.; Jennings, R. B.; Reimer, K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 1986, 74(5), 1124-1136.
26. Bradamante, S.; Piccinini, F.; Barenghi, L.; Bertelli, A. A.; De Jonge, R.; Beemster, P.; De Jong, J. W. Does resveratrol induce pharmacological preconditioning? Int. J. Tissue React., 2000, 22(1), 1-4.
27. Das, S.; Alagappan, V. K.; Bagchi, D.; Sharma, H. S.; Maulik, N.; Das, D. K. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vasc. Pharmacol., 2005, 42(5-6), 281-289.
28. Das, S.; Cordis, G. A.; Maulik, N.; Das, D. K. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am. J. Physiol. Heart Circ. Physiol., 2005, 288(1), H328-335.
29. De Jonge, R.; Out, M.; Maas, W. J.; De Jong, J. W. Preconditioning of rat hearts by adenosine A1 or A3 receptor activation. Eur. J. Pharmacol., 2002, 441(3), 165-172.
30. Hattori, R.; Otani, H.; Maulik, N.; Das, D. K. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am. J. Physiol. Heart Circ. Physiol., 2002, 282(6), H1988-1995.
31. Imamura, G.; Bertelli, A. A.; Bertelli, A.; Otani, H.; Maulik, N.; Das, D. K. Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am. J. Physiol. Heart Circ. Physiol., 2002, 282(6), H1996-2003.
32. Das, S.; Tosaki, A.; Bagchi, D.; Maulik, N.; Das, D. K. Resveratrol-mediated activation of cAMP response elementbinding protein through adenosine A3 receptor by Akt-dependent and-independent pathways. J. Pharmacol. Exp. Ther., 2005, 314(2), 762-769.
33. Das, S.; Fraga, C. G.; Das, D. K. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFkappaB. Free Radic. Res., 2006, 40(10), 1066-1075.
34. Bak, I.; Lekli, I.; Juhasz, B.; Nagy, N.; Varga, E.; Varadi, J.; Gesztelyi, R.; Szabo, G.; Szendrei, L.; Bacskay, I.; Vecsernyes, M.; Antal, M.; Fesus, L.; Boucher, F.; de Leiris, J.; Tosaki, A. Cardioprotective mechanisms of Prunus cerasus (sour cherry) seed extract against ischemia-reperfusion-induced damage in isolated rat hearts. Am. J. Physiol. Heart Circ. Physiol., 2006, 291(3), H1329-1336.
35. Gospodarowicz, D.; Abraham, J. A.; Schilling, J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc. Natl. Acad. Sci. USA, 1989, 86(19), 7311-7315.
36. Ferrara, N.; Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 1989, 161(2), 851-858.
37. de Vries, C.; Escobedo, J. A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 1992, 255(5047), 989-991.
38. Terman, B. I.; Dougher-Vermazen, M.; Carrion, M. E.; Dimitrov, D.; Armellino, D. C.; Gospodarowicz, D.; Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun., 1992, 187(3), 1579-1586.
39. Kaga, S.; Zhan, L.; Matsumoto, M.; Maulik, N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell. Cardiol., 2005, 39(5), 813-822.
40. Chen, C. Y.; Jang, J. H.; Li, M. H.; Surh, Y. J. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem. Biophys. Res. Commun., 2005, 331(4), 993-1000.
41. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature, 1993, 362(6423), 841-844.
42. Millauer, B.; Shawver, L. K.; Plate, K. H.; Risau, W.; Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 1994, 367(6463), 576-579.
43. Aiello, L. P.; Avery, R. L.; Arrigg, P. G.; Keyt, B. A.; Jampel, H. D.; Shah, S. T.; Pasquale, L. R.; Thieme, H.; Iwamoto, M. A.; Park, J. E.; et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl. J. Med., 1994, 331(22), 1480-1487.
44. Adamis, A. P.; Miller, J. W.; Bernal, M. T.; D'Amico, D. J.; Folkman, J.; Yeo, T. K.; Yeo, K. T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol., 1994, 118(4), 445-450.
45. Brown, L. F.; Yeo, K. T.; Berse, B.; Yeo, T. K.; Senger, D. R.; Dvorak, H. F.; van de Water, L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med., 1992, 176(5), 1375-1379.
46. Subbaramaiah, K.; Michaluart, P.; Chung, W. J.; Tanabe, T.; Telang, N.; Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann. N. Y. Acad. Sci., 1999, 889. 214-223.
47. Nakagawa, H.; Kiyozuka, Y.; Uemura, Y.; Senzaki, H.; Shikata, N.; Hioki, K.; Tsubura, A. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J. Cancer Res. Clin. Oncol., 2001, 127(4), 258-264.
48. Levenson, A. S.; Gehm, B. D.; Pearce, S. T.; Horiguchi, J.; Simons, L. A.; Ward, J. E., 3rd; Jameson, J. L.; Jordan, V. C. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int. J. Cancer, 2003, 104(5), 587-596.
49. Jazirehi, A. R.; Bonavida, B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther., 2004, 3(1), 71-84.
50. Shankar, S.; Chen, Q.; Siddiqui, I.; Sarva, K.; Srivastava, R. K. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J. Mol. Signal, 2007, 2. 7.
51. Scarlatti, F.; Sala, G.; Somenzi, G.; Signorelli, P.; Sacchi, N.; Ghidoni, R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J., 2003, 17(15), 2339-2341.
52. Dorrie, J.; Gerauer, H.; Wachter, Y.; Zunino, S. J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res., 2001, 61(12), 4731-4739.
53. Fulda, S.; Debatin, K. M. Sensitization for tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res., 2004, 64(1), 337-346.
54. Kuwajerwala, N.; Cifuentes, E.; Gautam, S.; Menon, M.; Barrack, E. R.; Reddy, G. P. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res., 2002, 62(9), 2488-2492.
55. Cao, Z.; Fang, J.; Xia, C.; Shi, X.; Jiang, B. H. trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin. Cancer Res., 2004, 10(15), 5253-5263.
56. Sexton, E.; Van Themsche, C.; LeBlanc, K.; Parent, S.; Lemoine, P.; Asselin, E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol. Cancer, 2006, 5. 45.
57. Zhang, Q.; Tang, X.; Lu, Q. Y.; Zhang, Z. F.; Brown, J.; Le, A. D. Resveratrol inhibits hypoxia-induced accumulation of hypoxiainducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther., 2005, 4(10), 1465-1474.
58. Marier, J. F.; Chen, K.; Prince, P.; Scott, G.; del Castillo, J. R.; Vachon, P. Production of ex vivo lipopolysaccharide-induced tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 is suppressed by trans-resveratrol in a concentration-dependent manner. Can. J. Vet. Res., 2005, 69(2), 151-154.
59. Sun, C.; Hu, Y.; Liu, X.; Wu, T.; Wang, Y.; He, W.; Wei, W. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet. Cytogenet., 2006, 165(1), 9-19.
60. Wu, H.; Liang, X.; Fang, Y.; Qin, X.; Zhang, Y.; Liu, J. Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomed. Pharmacother., 2008, 62(9), 613-621.
61. Azmi, A. S.; Bhat, S. H.; Hadi, S. M. Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett., 2005, 579(14), 3131-3135.
62. Kotha, A.; Sekharam, M.; Cilenti, L.; Siddiquee, K.; Khaled, A.; Zervos, A. S.; Carter, B.; Turkson, J.; Jove, R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., 2006, 5(3), 621-629.
63. Rezk, Y. A.; Balulad, S. S.; Keller, R. S.; Bennett, J. A. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am. J. Obstet. Gynecol., 2006, 194(5), e23-26.
64. Harikumar, K. B.; Kunnumakkara, A. B.; Sethi, G.; Diagaradjane, P.; Anand, P.; Pandey, M. K.; Gelovani, J.; Krishnan, S.; Guha, S.; Aggarwal, B. B. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer, 2010, 127(2), 257-268.
65. Lekli, I.; Szabo, G.; Juhasz, B.; Das, S.; Das, M.; Varga, E.; Szendrei, L.; Gesztelyi, R.; Varadi, J.; Bak, I.; Das, D. K.; Tosaki, A. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(2), H859-866.
66. Yildiz, F.; Terzi, A.; Coban, S.; Celik, H.; Aksoy, N.; Bitiren, M.; Cakir, H.; Ozdogan, M. K. Protective effects of resveratrol on small intestines against intestinal ischemia-reperfusion injury in rats. J. Gastroenterol. Hepatol., 2009, 24(11), 1781-1785.
67. Li, C.; Yan, Z.; Yang, J.; Chen, H.; Li, H.; Jiang, Y.; Zhang, Z. Neuroprotective effects of resveratrol on ischemic injury mediated by modulating the release of neurotransmitter and neuromodulator in rats. Neurochem. Int., 2010, 56(3), 495-500.
68. Kiziltepe, U.; Turan, N. N.; Han, U.; Ulus, A. T.; Akar, F. Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury. J. Vasc. Surg., 2004, 40(1), 138-145.
69. Zamin, L. L.; Dillenburg-Pilla, P.; Argenta-Comiran, R.; Horn, A. P.; Simao, F.; Nassif, M.; Gerhardt, D.; Frozza, R. L.; Salbego, C. Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of PI3-K pathway. Neurobiol. Dis., 2006, 24(1), 170-182.
70. Raval, A. P.; Dave, K. R.; Perez-Pinzon, M. A. Resveratrol mimics ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab., 2006, 26(9), 1141-1147.
71. Dore, S. Unique properties of polyphenol stilbenes in the brain: more than direct antioxidant actions; gene/protein regulatory activity. Neurosignals, 2005, 14(1-2), 61-70.
72. Sener, G.; Tugtepe, H.; Yuksel, M.; Cetinel, S.; Gedik, N.; Yegen, B. C. Resveratrol improves ischemia/reperfusion-induced oxidative renal injury in rats. Arch. Med. Res., 2006, 37(7), 822-829.
73. Chander, V.; Chopra, K. Role of nitric oxide in resveratrol-induced renal protective effects of ischemic preconditioning. J. Vasc. Surg., 2005, 42(6), 1198-1205.
74. Chander, V.; Chopra, K. Protective effect of resveratrol, a polyphenolic phytoalexin on glycerol-induced acute renal failure in rat kidney. Ren. Fail., 2006, 28(2), 161-169.
75. Leikert, J. F.; Rathel, T. R.; Wohlfart, P.; Cheynier, V.; Vollmar, A. M.; Dirsch, V. M. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation, 2002, 106(13), 1614-1617.
76. Rodrigo, R.; Bosco, C. Oxidative stress and protective effects of polyphenols: comparative studies in human and rodent kidney. A review. Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2006, 142(3-4), 317-327.
77. Bertelli, A. A.; Migliori, M.; Panichi, V.; Origlia, N.; Filippi, C.; Das, D. K.; Giovannini, L. Resveratrol, a component of wine and grapes, in the prevention of kidney disease. Ann. N. Y. Acad. Sci., 2002, 957. 230-238.
78. Klahr, S. Obstructive nephropathy. Kidney Int., 1998, 54(1), 286-300.
79. Vitaglione, P.; Morisco, F.; Caporaso, N.; Fogliano, V. Dietary antioxidant compounds and liver health. Crit. Rev. Food Sci. Nutr., 2004, 44(7-8), 575-586.
80. Gedik, E.; Girgin, S.; Ozturk, H.; Obay, B. D.; Buyukbayram, H. Resveratrol attenuates oxidative stress and histological alterations induced by liver ischemia/reperfusion in rats. World J. Gastroenterol., 2008, 14(46), 7101-7106.
81. Hassan-Khabbar, S.; Vamy, M.; Cottart, C. H.; Wendum, D.; Vibert, F.; Savouret, J. F.; Therond, P.; Clot, J. P.; Waligora, A. J.; Nivet-Antoine, V. Protective effect of post-ischemic treatment with trans-resveratrol on cytokine production and neutrophil recruitment by rat liver. Biochimie, 2010, 92(4), 405-410.
82. Stivala, L. A.; Savio, M.; Carafoli, F.; Perucca, P.; Bianchi, L.; Maga, G.; Forti, L.; Pagnoni, U. M.; Albini, A.; Prosperi, E.; Vannini, V. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem., 2001, 276(25), 22586-22594.
83. Sener, G.; Toklu, H. Z.; Sehirli, A. O.; Velioglu-Ogunc, A.; Cetinel, S.; Gedik, N. Protective effects of resveratrol against acetaminophen-induced toxicity in mice. Hepatol. Res., 2006, 35(1), 62-68.
84. King, R. E.; Kent, K. D.; Bomser, J. A. Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem.-Biol. Interact., 2005, 151(2), 143-149.
85. Sparrow, J. R.; Vollmer-Snarr, H. R.; Zhou, J.; Jang, Y. P.; Jockusch, S.; Itagaki, Y.; Nakanishi, K. A2E-epoxides damage DNA in retinal pigment epithelial cells. Vitamin E and other antioxidants inhibit A2E-epoxide formation. J. Biol. Chem., 2003, 278(20), 18207-18213.
86. Doganay, S.; Borazan, M.; Iraz, M.; Cigremis, Y. The effect of resveratrol in experimental cataract model formed by sodium selenite. Curr. Eye Res., 2006, 31(2), 147-153.
87. Szabo, M. E.; Gallyas, E.; Bak, I.; Rakotovao, A.; Boucher, F.; de Leiris, J.; Nagy, N.; Varga, E.; Tosaki, A. Heme oxygenase-1-related carbon monoxide and flavonoids in ischemic/reperfused rat retina. Invest. Ophthalmol. Vis. Sci., 2004, 45(10), 3727-3732.
88. Huang, H. M.; Liang, Y. C.; Cheng, T. H.; Chen, C. H.; Juan, S. H. Potential mechanism of blood vessel protection by resveratrol, a component of red wine. Ann. N Y Acad. Sci., 2005, 1042. 349-356.
89. Pendurthi, U. R.; Williams, J. T.; Rao, L. V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Atertio. Thromb. Vasc. Biol., 1999, 19(2), 419-426.
90. Di Santo, A.; Mezzetti, A.; Napoleone, E.; Di Tommaso, R.; Donati, M. B.; De Gaetano, G.; Lorenzet, R. Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells. J. Thromb Haemost., 2003, 1(5), 1089-1095.
91. Bertelli, A. A.; Giovannini, L.; Giannessi, D.; Migliori, M.; Bernini, W.; Fregoni, M.; Bertelli, A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React., 1995, 17(1), 1-3.
92. Olas, B.; Wachowicz, B.; Saluk-Juszczak, J.; Zielinski, T.; Kaca, W.; Buczynski, A. Antioxidant activity of resveratrol in endotoxinstimulated blood platelets. Cell Biol. Toxicol., 2001, 17(2), 117-125.
93. Ferrero, M. E.; Bertelli, A. E.; Fulgenzi, A.; Pellegatta, F.; Corsi, M. M.; Bonfrate, M.; Ferrara, F.; De Caterina, R.; Giovannini, L.; Bertelli, A. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am. J. Clin. Nutr., 1998, 68(6), 1208-1214.
94. McCarty, M. F. Potential utility of natural polyphenols for reversing fat-induced insulin resistance. Med. Hypotheses, 2005, 64(3), 628-635.
95. Su, H. C.; Hung, L. M.; Chen, J. K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocininduced diabetic rats. Am. J. Physiol. Endocrinol. Metab., 2006, 290(6), E1339-1346.
96. Thirunavukkarasu, M.; Penumathsa, S. V.; Koneru, S.; Juhasz, B.; Zhan, L.; Otani, H.; Bagchi, D.; Das, D. K.; Maulik, N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med., 2007, 43(5), 720-729.
97. Penumathsa, S. V.; Thirunavukkarasu, M.; Zhan, L.; Maulik, G.; Menon, V. P.; Bagchi, D.; Maulik, N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J. Cell Mol. Med., 2008, 12(6A), 2350-2361.
98. Chi, T. C.; Chen, W. P.; Chi, T. L.; Kuo, T. F.; Lee, S. S.; Cheng, J. T.; Su, M. J. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocininduced diabetic rats. Life Sci., 2007, 80(18), 1713-1720.
99. Ramadori, G.; Gautron, L.; Fujikawa, T.; Vianna, C. R.; Elmquist, J. K.; Coppari, R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology, 2009, 150(12), 5326-5333.
100. Ding, D. F.; You, N.; Wu, X. M.; Xu, J. R.; Hu, A. P.; Ye, X. L.; Zhu, Q.; Jiang, X. Q.; Miao, H.; Liu, C.; Lu, Y. B. Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. Am. J. Nephrol., 2010, 31(4), 363-374.
101. Schmatz, R.; Mazzanti, C. M.; Spanevello, R.; Stefanello, N.; Gutierres, J.; Correa, M.; da Rosa, M. M.; Rubin, M. A.; Chitolina Schetinger, M. R.; Morsch, V. M. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur. J. Pharmacol., 2009, 610(1-3), 42-48.
102. Zunino, S. Type 2 diabetes and glycemic response to grapes or grape products. J. Nutr., 2009, 139(9), 1794S-1800S.
103. Zou, J. G.; Wang, Z. R.; Huang, Y. Z.; Cao, K. J.; Wu, J. M. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int. J. Mol. Med., 2003, 11(3), 317-320.
104. Auger, C.; Teissedre, P. L.; Gerain, P.; Lequeux, N.; Bornet, A.; Serisier, S.; Besancon, P.; Caporiccio, B.; Cristol, J. P.; Rouanet, J. M. Dietary wine phenolics catechin, quercetin, and resveratrol efficiently protect hypercholesterolemic hamsters against aortic fatty streak accumulation. J. Agric. Food Chem., 2005, 53(6), 2015-2021.
105. Penumathsa, S. V.; Thirunavukkarasu, M.; Koneru, S.; Juhasz, B.; Zhan, L.; Pant, R.; Menon, V. P.; Otani, H.; Maulik, N. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J. Mol. Cell Cardiol., 2007, 42(3), 508-516.
106. Penumathsa, S. V.; Koneru, S.; Samuel, S. M.; Maulik, G.; Bagchi, D.; Yet, S. F.; Menon, V. P.; Maulik, N. Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor. Free Radic. Biol. Med., 2008, 45(7), 1027-1034.